CompletedPHASE1, PHASE2NCT02424175
Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.
Studying Sclerosing cholangitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Brigham and Women's Hospital
- Principal Investigator
- Joshua Korzenik, MDBrigham and Women's Hospital
- Intervention
- Fecal Microbiota Transplantation(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2018
Study locations (1)
- Brigham and Women's Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02424175 on ClinicalTrials.govOther trials for Sclerosing cholangitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07317193DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASEFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- RECRUITINGPHASE1NCT06825559Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseZydus Therapeutics Inc.
- RECRUITINGNCT06781242Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic CholestasisIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGNCT02545309Secondary Sclerosing Cholangitis in Critically Ill PatientsMedical University of Graz
- ACTIVE NOT RECRUITINGNANCT02601417The Necessity of Bile Cultures in Patients With Acute CholangitisSeoul National University Hospital